Jubilant Generics Receives USFDA Tentative Approval for Pantoprazole Sodium Oral Suspension
FDA’s tentative approval strengthens Jubilant Generics' US product pipeline and positions the company to launch Pantoprazole Sodium Delayed Release Oral Suspension following patent expiry later this year.
Jubilant Generics | 30/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy